Pulse Biosciences (PLSE) Expected to Announce Earnings on Wednesday

Pulse Biosciences (NASDAQ:PLSE) is expected to be announcing its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $0.50 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02).

Pulse Biosciences Trading Down 0.7%

Pulse Biosciences stock opened at $18.08 on Wednesday. The company has a market capitalization of $1.22 billion, a P/E ratio of -17.22 and a beta of 1.79. The firm’s fifty day simple moving average is $16.91 and its 200-day simple moving average is $16.42. Pulse Biosciences has a 1-year low of $13.77 and a 1-year high of $25.00.

Analyst Ratings Changes

Several brokerages recently commented on PLSE. Oppenheimer began coverage on shares of Pulse Biosciences in a report on Monday, July 7th. They issued an “outperform” rating and a $22.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Pulse Biosciences presently has a consensus rating of “Hold” and a consensus price target of $22.00.

Insider Buying and Selling

In related news, Director Robert W. Duggan purchased 34,659 shares of the firm’s stock in a transaction on Wednesday, September 10th. The shares were bought at an average cost of $14.66 per share, for a total transaction of $508,100.94. Following the transaction, the director directly owned 47,551,200 shares of the company’s stock, valued at approximately $697,100,592. This trade represents a 0.07% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CTO Darrin Uecker sold 25,000 shares of the firm’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $15.77, for a total transaction of $394,250.00. Following the completion of the sale, the chief technology officer owned 122,872 shares in the company, valued at $1,937,691.44. This represents a 16.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 95,000 shares of company stock worth $1,550,380 in the last quarter. 74.60% of the stock is currently owned by company insiders.

Institutional Trading of Pulse Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE grew its position in Pulse Biosciences by 0.7% in the 2nd quarter. Bank of America Corp DE now owns 783,536 shares of the company’s stock worth $11,824,000 after purchasing an additional 5,775 shares during the last quarter. Jane Street Group LLC grew its position in Pulse Biosciences by 20.6% in the 2nd quarter. Jane Street Group LLC now owns 24,251 shares of the company’s stock worth $366,000 after purchasing an additional 4,146 shares during the last quarter. Legal & General Group Plc grew its position in Pulse Biosciences by 57.7% in the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock worth $338,000 after purchasing an additional 8,197 shares during the last quarter. Norges Bank acquired a new stake in Pulse Biosciences in the 2nd quarter worth $302,000. Finally, Creative Planning grew its position in Pulse Biosciences by 26.3% in the 2nd quarter. Creative Planning now owns 18,971 shares of the company’s stock worth $286,000 after purchasing an additional 3,951 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.